JP2014527040A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014527040A5 JP2014527040A5 JP2014521801A JP2014521801A JP2014527040A5 JP 2014527040 A5 JP2014527040 A5 JP 2014527040A5 JP 2014521801 A JP2014521801 A JP 2014521801A JP 2014521801 A JP2014521801 A JP 2014521801A JP 2014527040 A5 JP2014527040 A5 JP 2014527040A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- pharmaceutical composition
- seq
- composition according
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 230000004761 fibrosis Effects 0.000 claims 3
- 206010038444 Renal failure chronic Diseases 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 201000000522 chronic kidney disease Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathy Diseases 0.000 claims 1
- 206010061835 Diabetic nephropathy Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 claims 1
- 201000004044 liver cirrhosis Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 201000009594 systemic scleroderma Diseases 0.000 claims 1
Claims (21)
- 線維化を特徴とする疾患又は障害を有する対象を治療するための、有効量の配列番号55のペプチドを含む医薬組成物。
- 前記ペプチドが配列番号5に対して少なくとも90％の同一性を有する、請求項1記載の医薬組成物。
- 前記ペプチドが配列番号5の配列を含む、請求項1記載の医薬組成物。
- 前記ペプチドが配列番号5からなる、請求項1記載の医薬組成物。
- 前記ペプチドが配列番号1のアミノ酸配列を含む、請求項1記載の医薬組成物。
- 前記ペプチドが配列番号1に対して少なくとも90％の同一性を有する、請求項1記載の医薬組成物。
- 前記ペプチドが配列番号1からなる、請求項1記載の医薬組成物。
- さらに薬学的に許容しうる担体を含む、請求項1記載の医薬組成物。
- 前記ペプチドを対象に経口的に投与する、請求項1記載の医薬組成物。
- 前記ペプチドを対象に局所的に、経腸的に、又は非経口的に投与する、請求項1記載の医薬組成物。
- 前記の疾患又は障害が、糖尿病性腎症、肝硬変、特発性肺線維症、関節リウマチ、アテローム性動脈硬化症、心臓線維症、全身性硬化症、腎炎、及び強皮症である、請求項1記載の医薬組成物。
- 前記の疾患又は障害が慢性腎疾患(CKD)である、請求項1記載の医薬組成物。
- 1日あたり0.0001〜10,000 mg／kg体重の前記ペプチドの用量を対象に投与する、請求項1記載の医薬組成物。
- 前記の投与する用量が1日あたり1〜100 mg／kg体重である、請求項13記載の医薬組成物。
- 請求項1〜14のいずれか1項記載の医薬組成物及び使用説明書を含むキット。
- 配列番号55のアミノ酸配列を含む、線維化を特徴とする疾患又は障害を治療するためのペプチド。
- 配列番号5のアミノ酸配列を含む、請求項16記載のペプチド。
- 配列番号5のアミノ酸配列からなる、請求項16記載のペプチド。
- 配列番号1のアミノ酸配列を含む、請求項16記載のペプチド。
- 配列番号1のアミノ酸配列からなる、請求項16記載のペプチド。
- 請求項16〜20のいずれか1項記載のペプチド及び使用説明書を含むキット。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161509340P | 2011-07-19 | 2011-07-19 | |
| US61/509,340 | 2011-07-19 | ||
| US201261662337P | 2012-06-20 | 2012-06-20 | |
| US61/662,337 | 2012-06-20 | ||
| PCT/US2012/047468 WO2013013085A2 (en) | 2011-07-19 | 2012-07-19 | Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014527040A JP2014527040A (ja) | 2014-10-09 |
| JP2014527040A5 true JP2014527040A5 (ja) | 2015-08-20 |
Family
ID=47558730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014521801A Pending JP2014527040A (ja) | 2011-07-19 | 2012-07-19 | 抗−線維化ペプチド並びに線維化を特徴とする疾患及び障害を治療するための方法における該抗−線維化ペプチドの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20140057831A1 (ja) |
| EP (1) | EP2734220A4 (ja) |
| JP (1) | JP2014527040A (ja) |
| CN (2) | CN106478776A (ja) |
| AU (1) | AU2012283924A1 (ja) |
| BR (1) | BR112014001268A2 (ja) |
| CA (1) | CA2842330A1 (ja) |
| HK (1) | HK1198333A1 (ja) |
| IL (1) | IL230510A0 (ja) |
| RU (1) | RU2014105513A (ja) |
| WO (1) | WO2013013085A2 (ja) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170232276A1 (en) * | 2014-09-30 | 2017-08-17 | Primegen Biotech, Llc | Treatment of fibrosis using deep tissue heating and stem cell therapy |
| US20160137714A1 (en) * | 2014-11-12 | 2016-05-19 | Thrasos Innovation, Inc. | Peptides with enhanced stability and their use in methods for treating diseases |
| EP3289073A4 (en) | 2015-05-01 | 2019-07-17 | University of Miami | METHOD AND COMPOSITIONS FOR THE CONVERSION OF NON-ENDOCRINE PANCREATIC TISSUE IN INSULIN-PRODUCING CELLS |
| CN114621318A (zh) * | 2015-05-12 | 2022-06-14 | 加利福尼亚大学董事会 | 用于炎症和纤维化的肽治疗 |
| US10844392B2 (en) * | 2015-06-05 | 2020-11-24 | Ibio, Inc. | Materials and methods for producing endostatin fusion polypeptides in plant cells |
| WO2019133950A1 (en) * | 2017-12-30 | 2019-07-04 | The Regents Of The University Of Colorado, A Body Corporate | Smad7 for treatment and prevention of posterior capsule opacification |
| JP6933394B2 (ja) * | 2018-09-06 | 2021-09-08 | マリン エッセンス バイオサイエンシズ コーポレーション オブ ユーエスエーＭａｒｉｎｅ Ｅｓｓｅｎｃｅ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ ｏｆ ＵＳＡ | 組織再生誘導のためのバイオマテリアルデバイスおよび局所用組成物 |
| AU2019366366A1 (en) * | 2018-10-22 | 2021-05-20 | William D. Carlson | Therapeutic combinations of TDFRPs and additional agents and methods of use |
| EP3996736A4 (en) * | 2019-07-10 | 2023-05-24 | Musc Foundation for Research Development | ENDOSTATIN PEPTIDES FOR THE TREATMENT OF TUMORS, FIBROSIS AND ACUTE LUNG INJURY |
| CN111704653B (zh) * | 2020-06-08 | 2023-10-03 | 深圳市图微安创科技开发有限公司 | 靶向于纤连蛋白衍生肽的抑制剂多肽化合物及其用途 |
| WO2022197855A1 (en) * | 2021-03-16 | 2022-09-22 | Therapeutics By Design, LLC | Therapeutic combinations of tdfrps and additional agents and methods of use for the reversal of fibrosis |
| CN113069531B (zh) * | 2021-04-09 | 2023-02-28 | 南开大学 | 一种防疤痕皮肤创伤修复用水凝胶及其制备方法 |
| CN116768974A (zh) * | 2022-03-11 | 2023-09-19 | 中山大学 | 用于预防和/或治疗肾纤维化的多肽化合物 |
| WO2024081245A1 (en) | 2022-10-10 | 2024-04-18 | Therapeutics By Design, LLC | Tissue differentiation factor related polypeptides (tdfrps) for the treatment of myocardial injury |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE244574T1 (de) * | 1996-03-22 | 2003-07-15 | Curis Inc | Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns |
| JP4654029B2 (ja) * | 2002-06-17 | 2011-03-16 | トラソス インコーポレイテッド | 単一ドメインｔｄｆ関連化合物およびその類似体 |
| CA2571218C (en) * | 2004-06-17 | 2015-11-03 | William D. Carlson | Tdf-related compounds and analogs thereof |
| HUE026634T2 (en) * | 2005-09-20 | 2016-07-28 | Thrasos Innovation Inc | TDF-related compounds and analogues thereof |
| EP2387612A4 (en) * | 2009-01-16 | 2013-02-13 | Agency Science Tech & Res | METHOD OF INHIBITING THE PROLIFERATION OF STEEL CELLS |
| US8642834B2 (en) * | 2009-02-27 | 2014-02-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| US20120183543A1 (en) * | 2009-05-08 | 2012-07-19 | Novartis Ag | Diagnostic biomarkers for fibrotic disorders |
-
2012
- 2012-07-19 CN CN201610543024.0A patent/CN106478776A/zh active Pending
- 2012-07-19 CA CA2842330A patent/CA2842330A1/en not_active Abandoned
- 2012-07-19 AU AU2012283924A patent/AU2012283924A1/en not_active Abandoned
- 2012-07-19 BR BR112014001268A patent/BR112014001268A2/pt not_active IP Right Cessation
- 2012-07-19 JP JP2014521801A patent/JP2014527040A/ja active Pending
- 2012-07-19 RU RU2014105513/04A patent/RU2014105513A/ru not_active Application Discontinuation
- 2012-07-19 EP EP12814119.9A patent/EP2734220A4/en not_active Withdrawn
- 2012-07-19 WO PCT/US2012/047468 patent/WO2013013085A2/en active Application Filing
- 2012-07-19 US US13/553,685 patent/US20140057831A1/en not_active Abandoned
- 2012-07-19 CN CN201280045650.7A patent/CN103890003B/zh not_active Expired - Fee Related
-
2014
- 2014-01-16 IL IL230510A patent/IL230510A0/en unknown
- 2014-11-24 HK HK14111848.5A patent/HK1198333A1/zh unknown
-
2015
- 2015-08-05 US US14/818,652 patent/US20160058829A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014527040A5 (ja) | ||
| RU2014105513A (ru) | Противофиброзные пептиды и их применение в способах лечения заболеваний и расстройств, характеризующихся фиброзом | |
| JP2013520405A5 (ja) | ||
| JP2015517488A5 (ja) | ||
| HRP20180425T1 (hr) | Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline | |
| JP2015517489A5 (ja) | ||
| JP2015518818A5 (ja) | ||
| JP2014508753A5 (ja) | ||
| PH12018550201A1 (en) | Hepatitis b antiviral agents | |
| JP2015057436A5 (ja) | ||
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| CL2011000353A1 (es) | Compuestos derivados de 1-{4-[metil(7h-pirrolo[2,3-d]pirimidin-4-il)amino]ciclohexil}metanosulfonamida o una sal farmaceuticamente aceptable; forma cristalina de la sal maleato; procedimiento de preparacion; composicion farmaceutica; y uso para tratar enfermedades alergicas, cancer, lupus. | |
| HRP20201081T1 (hr) | Inhibitorni peptidi porijeklom od trem-sličnog transkripta 1 (tlt-1) i njihove uporabe | |
| NZ708501A (en) | Treatment of pulmonary disease | |
| JP2011528332A5 (ja) | ||
| JP2013542247A5 (ja) | ||
| JP2012144574A5 (ja) | ||
| JP2013505205A5 (ja) | ||
| JP2013509429A5 (ja) | ||
| JP2015513318A5 (ja) | ||
| EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| JP2011509303A5 (ja) | ||
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| JP2012092123A5 (ja) | ||
| BR112014015142A2 (pt) | di-hidropirimidinoisoquinolinonas e composições farmacêuticas das mesmas para o tratamento de distúrbios inflamatórios |